GS-6615
Phase 1Completed 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Long QT Syndrome
Conditions
Long QT Syndrome
Trial Timeline
May 1, 2013 → Nov 1, 2014
NCT ID
NCT01849003About GS-6615
GS-6615 is a phase 1 stage product being developed by Gilead Sciences for Long QT Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT01849003. Target conditions include Long QT Syndrome.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01849003 | Phase 1 | Completed |
Competing Products
16 competing products in Long QT Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Ensitrelvir | Shionogi | Phase 2 | 52 |
| TBM100 | Novartis | Approved | 85 |
| GS-6615 + Placebo to match GS-6615 + Placebo to match dofetilide + Dofetilide | Gilead Sciences | Phase 1 | 32 |
| Eleclazine | Gilead Sciences | Phase 1 | 32 |
| Eleclazine | Gilead Sciences | Phase 1 | 32 |
| Placebo + Ranolazine | Gilead Sciences | Phase 2 | 51 |
| Eleclazine + Eleclazine placebo | Gilead Sciences | Phase 3 | 76 |
| Nirmatrelvir + Ritonavir + Placebo | Pfizer | Phase 2 | 51 |
| Staccato alprazolam | UCB | Phase 3 | 74 |
| Staccato alprazolam | UCB | Phase 3 | 74 |
| N-803 (IL-15 Superagonist) | ImmunityBio | Phase 2 | 49 |
| Anktiva | ImmunityBio | Phase 2 | 49 |
| UX007 | Ultragenyx Pharmaceutical | Phase 2 | 47 |
| triheptanoin | Ultragenyx Pharmaceutical | Pre-clinical | 18 |
| Triheptanoin | Ultragenyx Pharmaceutical | Phase 3 | 72 |
| Triheptanoin | Ultragenyx Pharmaceutical | Pre-clinical | 18 |